Efficacy and safety of Edaravone Dexborneol in acute large vessel occlusion patients with successful recanalization after endovascular treatment.

作者：Xiangliang Chen, Li-Yuan Wang, Yunyun Xiong, Zhenqiang Zhao, KaiLai Huang, Zhenhui Duan, Kangmeng Wang, Chun-Hua Yun, Mei Yang, Tianyi Xu, Wenhua Liu, Wei Li · 发表于：Journal of Stroke & Cerebrovascular Diseases · 年份：2025 · DOI：10.1016/j.jstrokecerebrovasdis.2025.108505 · 被引用次数：1 · 研究领域：Medicine

BACKGROUND AND PURPOSE Edaravone dexborneol (ED) is a novel cytoprotective drug for treating acute ischemic stroke (AIS) with synergistic antioxidant and anti-inflammatory effects. This study aimed to assess the efficacy and safety of ED in acute large vessel occlusion (LVO) patients with successful recanalization after endovascular treatment (EVT). METHODS Data from three comprehensive stroke centers of consecutive AIS-LVO patients treated with EVT were retrospectively included in this study. Patients were divided into ED and non-ED groups. The primary efficacy outcome was the shift of the modified Rankin Scale (mRS) score at 90 days. The secondary efficacy outcomes included functional independence (mRS score 0-2) and excellent outcome (mRS 0-1) at 90 days. Safety outcomes included mortality within 90 days and symptomatic intracranial hemorrhage (sICH) within 48 hours. RESULTS A total of 231 patients with successful recanalization after EVT were included in the analysis, of whom 84 (36.4%) were in the ED group and 147 (63.6%) were in the non-ED group. After adjustment for potential confounders, ED was associated with a favorable shift in the 90-day mRS score (common adjusted odds ratio [aOR], 2.09; 95% confidence interval [CI], 1.05-4.14; P = 0.035). The proportions of sICH (4.76% vs. 7.41%; aOR, 0.44; 95% CI, 0.10-2.02; P = 0.290) and 90-day mortality (6.41% vs. 8.8%; aOR, 0.37; 95%CI, 0.06-2.31; P = 0.280) were numerically lower in the ED group than in the non-ED group...